[300 Pages Report] The global hemostatic gels market was valued at US$ 957.1 Million in 2021, and is expected to expand at a CAGR of 6.8% to reach US$ 1.9 Billion by 2032. According to a recent study by Future Market Insights, porcine-based hemostatic gels are leading the market with a market share of about 45% in 2021 among the material types.
| Data Points | Market Insights |
|---|---|
| Hemostatic Gels Market Base Year Value (2021) | US$ 957.1 Million |
| Estimated Market Size (2022) | US$ 1.0 Billion |
| Projected Market Valuation (2032) | US$ 1.9 Billion |
| Value-based CAGR (2022 to 2032) | 6.8% |
| Market Share of Top 5 Countries | 45.9% |
Hemostatic gel is used as an assistant or alternative to hemostat devices to manage bleeding or wound closure. Blood loss is one of the main causes of death in physical trauma. It is important to manage blood loss and achieve quicker clotting than the natural clotting process which is occurred in the body. To achieve blood clotting more quickly, physicians occasionally use hemostatic agents such as a hemostatic gel. These gels may promote clotting and thereby stop or control bleeding.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for hemostatic gels was approximately 21.8% of the overall US$ 4.3 Bn of the global hemostats market in 2021. Sales of hemostatic gels increased at a CAGR of 5.4% between 2017 to 2021, owing to the growing volume of surgical procedures.
Growing interest in developing new hemostatic agents is due to unmet needs in modifying uncontrolled hemorrhages in emergency care, surgical procedures, and frontline situations. Even though a wide range of hemostats are available, the development of ideal hemostatic agents such as hemostatic gel formulations that offer including the ability to successfully and instantly manage blood loss, excellent mechanical properties, biocompatibility, antibacterial effect, strong tissue adhesion properties, and biodegradability, under wet and active conditions, remains a challenge.
Benefiting from biocompatibility, high porosity, injectability, and ease of handling, polymeric hydrogels with outstanding hemostatic properties have been receiving consideration over the last decade. Furthermore, the development of novel technologies to cater to the demand for high-quality gel-forming hemostatic agents will drive the overall hemostatic gels market.
The market is projected to witness lucrative growth during forecast period owing to increasing volumes of surgical procedures. According to WHO, annually, a surprising 310 million major surgeries are performed globally; and in U.S. and Europe, approximately 45 and 20 million surgeries are carried out respectively every year. This is attributed to the growing prevalence of obesity and other lifestyle diseases, rising prevalence of orthopaedic disease, and the growing occurrence of spinal and sports-related injuries.
Moreover, in both developed and emerging countries the number of hospitals and surgical centers is growing. The demand for hemostats such as hemostatic gels is high in these newly established hospitals and surgical centers due to the growing patient population base.
For instance, in the last quarter of 2020, U.K. Prime Minister Boris Johnson declared an investment of US4 4.3 Bn for 40 hospitals and certain schemes for upcoming funding for 48 hospitals by 2030.
Also, Steward Health Care in March 2021 announced plans to construct a new hospital in Washington. Thus, owing to the above-mentioned factors, the global hemostatic gels market is expected to grow at a CAGR of 6.8% during the forecast period.
Hemostasis has high clinical importance in preventive, surgical, and emergency circumstances as blood loss may cause substantial diseases and deaths in civil and military individuals owing to bleeding problems rising from surgery, trauma injuries, and as hereditary, disease-related, or drug-induced blood syndromes.
For externally accessible injuries, a range of natural and synthetic biomaterials have to go through strong research, leading to hemostatic technologies including bandages, dressings, fibrin glues, tourniquets, tamponades, and hemostatic powders.
In contrast, treatment of internal non-compressible hemorrhage still severely relies on transfusion of pure blood or blood hemostatic components such as platelets, coagulation factors, and fibrinogens. Transfusion of platelets may experience significant challenges of high cost, limited availability, contamination risks, short shelf-life, performance variability, low portability, and immunological adverse reactions.
The usage of these blood hemostatic components provides only partial mechanisms for hemostasis. Through such concerns, interdisciplinary research is being conducted for the development of hemostatic gels that can be manufactured conveniently, and administered intravenously to mimic, leverage, and amplify physiological hemostatic mechanisms. This is expected to create opportunities for growth in the market for the development of effective and efficient hemostats.
Principal Consultant
“Increasing Incidence of Lifestyle Related Disorders is Driving Demand for Hemostatic Gels”
The U.S. dominated the North America hemostatic gels market, accounting for 82% of the total markets share in 2021. Rising prevalence of cardiovascular disorders, diabetes, and cancer in the U.S. is propelling the volume of surgical procedures, thereby necessitating hemostatic gels.
With the global rise in the incidence of chronic diseases, the volume of surgical procedures is expected to increase in the forthcoming years, which is expected to drive demand hemostatic gels for blood loss management.
According to the CDC, around 150 million Americans are suffering from at least one chronic condition, which leads to the need for surgery. With the growing incidence of chronic diseases, the number of injuries and surgeries is expected to increase, thereby increasing the usage of hemostatic gels in the U.S.
“Rising Expenditure on Healthcare Infrastructure Will Augment Sales of Hemostatic Gels”
Demand for hemostatic gels in India is set to increase at a 7.4% CAGR over the assessment period. The market in India is driven by increasing demand for hemostatic gels due to growing government initiatives to create awareness about the product.
For instance, in November 2020, the transport department of the Rajasthan government mandated the addition of feracrylum, a hemostatic gel, in the first aid of all vehicles that are being registered from November 2020 following a direction of the high court. Feracrylum has been recognized to be a hemostatic agent by several clinical studies.
“Growing Trend of Medical Tourism in the U.K. Will Fuel the Adoption of Hemostatic Gels”
Sales in the U.K. market are projected to increase at a 7.1% CAGR over the forecast period. As per the British heart foundation (UK) and its heart and circulatory disease statistics, in 2019, there has been a substantial surge in the number of cardiac surgeries such as aortic valve replacement and angioplasty in the U.K.
Hemostatic gels have higher application in cardiovascular surgeries due to better clinical outcomes compared to other wound closure techniques. Thus, a growing number of cardiac surgeries is expected to spur demand for effective hemostatic gels in the U.K.
“Increaisng Establishment of Hospitals and Ambulatory Centers in China Will Propel Demand for Hemostatic Gels”
China held approximately 38.0% of the East Asia hemostatic gels market in 2021. As per the report, sales are forecast to grow at a 8.0% CAGR through 2032.
The government in China is investing heavily in the construction of healthcare infrastructure such as hospitals and clinics. As per an article published in 2020, China announced an investment of US$ 4.6 Bn for the construction of hospitals in Wuhan.
There are now about 26,000 hospitals in China, more than in any other country; among them 60% are public and 40% are in the private sector. The significant growth in the number of hospitals and surgical centers is expected to boost sales of hemostatic gels.
“Sales of Porcine-based Hemostatic Gels to Gain Traction”
Based on product type, the porcine-based hemostatic gels segment held the highest market share of about 45% in 2021. As per the report, demand in the segment is expected to increase at a CAGR of 5.7% by the end of the forecast period. Ease of application, efficacy, biocompatibility, and cost-effectiveness are some of the key benefits offered by porcine-based hemostatic gels.
“Adoption of Hemostatic Gels for Cardiovascular Surgeries Will Increase”
In terms of indication, demand for hemostatic gels for cardiovascular surgeries will account for 33.1% of the total market share by 2032. Blood loss is one of the most common obstacle in cardiac surgeries, particularly following aortic involvements which leads to extended operating times, increased bleeding, and a higher risk of postoperative morbidity and mortality. The use of hemostatic gels, especially in patients undergoing cardiac surgical procedures, is safe and effective in reducing time to hemostasis, reducing transfusion of blood products, and improving patient outcomes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Leading players operating in the global hemostatic gels market are launching innovative products to meet the demand for a hemostatic gel that can be easily and specifically applied, particularly for irregular fractures where bandages can be difficult, and powders are messy and can cause uneasiness. For instance:
With several competitors in hemostatic gels manufacturing, the overall market is highly fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships, and collaborations. For instance:
| Attributes | Details |
|---|---|
| Estimated Market Size (2022) | US$ 1 Billion |
| Projected Market Valuation (2032) | US$ 1.9 Billion |
| Value-based CAGR (2022-2032) | 6.8% |
| Forecast Period | 2017 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa |
| Key Market Segments Covered | Material, Indication, End User, and Region |
| Key Companies Profiled |
|
The global hemostatic gels market is worth US$ 957.1 Mn in 2021 and is set to expand 2.1X over the next ten years.
The hemostatic gels market is expected to reach US$ 1.9 Bn by the end of 2032, with sales revenue expected to register at 6.8% CAGR.
The growing volume of surgical procedures and the increasing need for hemostatic gels in blood loss management are some of the key trends in this market.
The U.S., the U.K., India, China, and Brazil are expected to drive demand for the hemostatic gels industry.
North America is one of the key markets for hemostatic gels, with the U.S. accounting for about 82% of the North American hemostatic gels market in the year 2021.
Demand for hemostatic gels in Europe is expected to register a growth of 7.1% over the next ten years.
The U.S., the U.K., India, and China are the key producers of hemostatic gels.
Baxter, Bio-Chem LLC, Clinician's Choice Dental Products Inc., Cresilon, Inc., Dsi Ltd., Endovision Co., Ltd, Ethicon US, LLC, F&A Medical, Prevestdenpro, Septodont, Teleflex Incorporated, Ultradent Products Inc. All, Vladmiva And Medcura, Inc., Are Some Of The Key Players In The Hemostatic Gels Industry.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Development and Innovation Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Key Promotional Strategies, By Manufacturers
4.3. Pipeline Assessment
4.4. Value Chain Analysis
4.5. Regulatory Landscape
4.6. PESTEL analysis
4.7. Porter’s analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Demand for Targeted Drug Therapies.
5.2.2. Rapidly Increasing volume of surgical procedures
5.2.3. Rising Prevalence of Chronic Disease
5.2.4. Increasing Investments In R&D
5.2.5. Technological Advancements In Hemostatic Agents
5.2.6. Availability Of Technologically Advanced Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1. COVID19 and Impact Analysis
6.1.1. Revenue By Material
6.1.2. Revenue By Indication
6.1.3. Revenue By End User
6.1.4. Revenue By Region
6.2. 2021 Market Scenario
7. Global Hemostatic Gels Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032, By Material
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Material, 2017–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Material, 2022–2032
8.3.1. Bovine Based
8.3.2. Porcine Based
8.3.3. Polymer Based
8.4. Market Attractiveness Analysis By Material
9. Global Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn), By Indication, 2017–2021
9.3. Current and Future Market Size (US$ Mn) and Forecast By Indication, 2022–2032
9.3.1. General Surgery
9.3.2. Dental Surgery
9.3.3. Veterinary Surgery
9.3.4. Cardiovascular Surgery
9.3.5. Orthopedic Surgery
9.3.6. Others
9.4. Market Attractiveness Analysis By Indication
10. Global Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032, By End-User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn), By End-User, 2017–2021
10.3. Current and Future Market Size (US$ Mn) and Forecast By End-User, 2022–2032
10.3.1. Hospitals
10.3.2. Speciality Clinics
10.3.3. Veterinary Settings
10.3.4. Ambulatory Surgical Centers
10.3.5. Online Sales
10.4. Market Attractiveness Analysis By End-User
11. Global Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2017–2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Material
12.3.3. By Indication
12.3.4. By End-User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Material
12.4.3. By Indication
12.4.4. By End-User
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. U.S. Hemostatic Gels Market Analysis
12.7.1.1. .Introduction
12.7.1.2. Market Analysis and Forecast by Market Taxonomy
12.7.1.2.1. By Material
12.7.1.2.2. By Indication
12.7.1.2.3. By End-User
12.7.2. Canada Hemostatic Gels Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast by Market Taxonomy
12.7.2.2.1. By Material
12.7.2.2.2. By Indication
12.7.2.2.3. By End-User
13. Latin America Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2017–2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Material
13.3.3. By Indication
13.3.4. By End-User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Material
13.4.3. By Indication
13.4.4. By End-User
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. Mexico Hemostatic Gels Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Material
13.7.1.2.2. By Indication
13.7.1.2.3. By End-User
13.7.2. Brazil Hemostatic Gels Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Material
13.7.2.2.2. By Indication
13.7.2.2.3. By End-User
13.7.3. Argentina Hemostatic Gels Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast by Market Taxonomy
13.7.3.2.1. By Material
13.7.3.2.2. By Indication
13.7.3.2.3. By End-User
14. Europe Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2017–2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. Poland
14.3.1.7. Russia
14.3.1.8. Nordic Countries
14.3.1.9. BENULUX
14.3.1.10. Rest of Europe
14.3.2. By Material
14.3.3. By Indication
14.3.4. By End-User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Material
14.4.3. By Indication
14.4.4. By End-User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Hemostatic Gels Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Material
14.8.1.2.2. By Indication
14.8.1.2.3. By End-User
14.8.2. Italy Hemostatic Gels Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Material
14.8.2.2.2. By Indication
14.8.2.2.3. By End-User
14.8.3. France Hemostatic Gels Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Material
14.8.3.2.2. By Indication
14.8.3.2.3. By End-User
14.8.4. U.K. Hemostatic Gels Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Material
14.8.4.2.2. By Indication
14.8.4.2.3. By End-User
14.8.5. Spain Hemostatic Gels Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Material
14.8.5.2.2. By Indication
14.8.5.2.3. By End-User
14.8.6. Poland Hemostatic Gels Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Material
14.8.6.2.2. By Indication
14.8.6.2.3. By End-User
14.8.7. Russia Hemostatic Gels Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Material
14.8.7.2.2. By Indication
14.8.7.2.3. By End-User
14.8.8. Nordic Countries Hemostatic Gels Market Analysis
14.8.8.1. Introduction
14.8.8.2. Market Analysis and Forecast by Market Taxonomy
14.8.8.2.1. By Material
14.8.8.2.2. By Indication
14.8.8.2.3. By End-User
14.8.9. BENELUX Hemostatic Gels Market Analysis
14.8.9.1. Introduction
14.8.9.2. Market Analysis and Forecast by Market Taxonomy
14.8.9.2.1. By Material
14.8.9.2.2. By Indication
14.8.9.2.3. By End-User
15. South Asia Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2017–2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Material
15.3.3. By Indication
15.3.4. By End-User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Material
15.4.3. By Indication
15.4.4. By End-User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. India Hemostatic Gels Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Material
15.7.1.2.2. By Indication
15.7.1.2.3. By End-User
15.7.2. Indonesia Hemostatic Gels Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Material
15.7.2.2.2. By Indication
15.7.2.2.3. By End-User
15.7.3. Malaysia Hemostatic Gels Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Material
15.7.3.2.2. By Indication
15.7.3.2.3. By End-User
15.7.4. Thailand Hemostatic Gels Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Material
15.7.4.2.2. By Indication
15.7.4.2.3. By End-User
16. East Asia Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2017–2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By By Material
16.3.3. By Indication
16.3.4. By End-User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Material
16.4.3. By Indication
16.4.4. By End-User
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. China Hemostatic Gels Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Material
16.7.1.2.2. By Indication
16.7.1.2.3. By End-User
16.7.2. Japan Hemostatic Gels Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Material
16.7.2.2.2. By Indication
16.7.2.2.3. By End-User
16.7.3. South Korea Hemostatic Gels Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Material
16.7.3.2.2. By Indication
16.7.3.2.3. By End-User
17. Oceania Hemostatic Gels Market 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Material
17.3.3. By Indication
17.3.4. By End-User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Material
17.4.3. By Indication
17.4.4. By End-User
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. Australia Hemostatic Gels Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Material
17.7.1.2.2. By Indication
17.7.1.2.3. By End-User
17.7.2. New Zealand Hemostatic Gels Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Material
17.7.2.2.2. By Indication
17.7.2.2.3. By End-User
18. Middle East and Africa (MEA) Hemostatic Gels Market Analysis 2017–2021 and Forecast 2022–2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2017–2021
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. Turkey
18.3.1.2. GCC Countries
18.3.1.3. South Africa
18.3.1.4. Rest of Middle East and Africa
18.3.2. By Material
18.3.3. By Indication
18.3.4. By End-User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Material
18.4.3. By Indication
18.4.4. By End-User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. Turkey Hemostatic Gels Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Material
18.7.1.2.2. By Indication
18.7.1.2.3. By End-User
18.7.2. GCC Countries Hemostatic Gels Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Material
18.7.2.2.2. By Indication
18.7.2.2.3. By End-User
18.7.3. South Africa & North Africa Hemostatic Gels Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Material
18.7.3.2.2. By Indication
18.7.3.2.3. By End-User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Company Share Analysis
19.4. Market Presence Analysis
19.4.1. By Regional footprint of Players
19.4.2. Product footprint by Players
19.4.3. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Market Concentration
20.4. Competition Deep Dive (Tentative List)
20.4.1. Baxter
20.4.1.1.1. Overview
20.4.1.1.2. Product Portfolio
20.4.1.1.3. Key Financials
20.4.1.1.4. Sales Footprint
20.4.1.1.5. Strategy Overview
20.4.2. Bio-Chem LLC
20.4.2.1.1. Overview
20.4.2.1.2. Product Portfolio
20.4.2.1.3. Key Financials
20.4.2.1.4. Sales Footprint
20.4.2.1.5. Strategy Overview
20.4.3. Clinician's Choice Dental Products Inc.
20.4.3.1.1. Overview
20.4.3.1.2. Product Portfolio
20.4.3.1.3. Key Financials
20.4.3.1.4. Sales Footprint
20.4.3.1.5. Strategy Overview
20.4.4. Cresilon –VETIGEL
20.4.4.1.1. Overview
20.4.4.1.2. Product Portfolio
20.4.4.1.3. Key Financials
20.4.4.1.4. Sales Footprint
20.4.4.1.5. Strategy Overview
20.4.5. DSI Ltd.
20.4.5.1.1. Overview
20.4.5.1.2. Product Portfolio
20.4.5.1.3. Key Financials
20.4.5.1.4. Sales Footprint
20.4.5.1.5. Strategy Overview
20.4.6. ENDOVISION CO.,LTD
20.4.6.1.1. Overview
20.4.6.1.2. Product Portfolio
20.4.6.1.3. Key Financials
20.4.6.1.4. Sales Footprint
20.4.6.1.5. Strategy Overview
20.4.7. Ethicon US, LLC
20.4.7.1.1. Overview
20.4.7.1.2. Product Portfolio
20.4.7.1.3. Key Financials
20.4.7.1.4. Sales Footprint
20.4.7.1.5. Strategy Overview
20.4.8. F&A Medical
20.4.8.1.1. Overview
20.4.8.1.2. Product Portfolio
20.4.8.1.3. Key Financials
20.4.8.1.4. Sales Footprint
20.4.8.1.5. Strategy Overview
20.4.9. PrevestDenPro
20.4.9.1.1. Overview
20.4.9.1.2. Product Portfolio
20.4.9.1.3. Key Financials
20.4.9.1.4. Sales Footprint
20.4.9.1.5. Strategy Overview
20.4.10. Septodont
20.4.10.1.1. Overview
20.4.10.1.2. Product Portfolio
20.4.10.1.3. Key Financials
20.4.10.1.4. Sales Footprint
20.4.10.1.5. Strategy Overview
20.4.11. Teleflex Incorporated
20.4.11.1.1. Overview
20.4.11.1.2. Product Portfolio
20.4.11.1.3. Key Financials
20.4.11.1.4. Sales Footprint
20.4.11.1.5. Strategy Overview
20.4.12. Ultradent Products Inc. All
20.4.12.1.1. Overview
20.4.12.1.2. Product Portfolio
20.4.12.1.3. Key Financials
20.4.12.1.4. Sales Footprint
20.4.12.1.5. Strategy Overview
20.4.13. VladMiVa
20.4.13.1.1. Overview
20.4.13.1.2. Product Portfolio
20.4.13.1.3. Key Financials
20.4.13.1.4. Sales Footprint
20.4.13.1.5. Strategy Overview
20.4.14. Medcura, Inc.,
20.4.14.1.1. Overview
20.4.14.1.2. Product Portfolio
20.4.14.1.3. Key Financials
20.4.14.1.4. Sales Footprint
20.4.14.1.5. Strategy Overview
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Hemostatic Gels Market
